Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G.

Nat Genet. 2014 Jun 29. doi: 10.1038/ng.3016. [Epub ahead of print]

PMID:
24974848
[PubMed - as supplied by publisher]
2.

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.

Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M.

Br J Cancer. 2014 Jul 15;111(2):220-6. doi: 10.1038/bjc.2014.312. Epub 2014 Jun 10.

PMID:
24918816
[PubMed - in process]
3.

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC-Letter.

Avan A, Maftouh M, Avan A, Tibaldi C, Zucali PA, Giovannetti E.

Clin Cancer Res. 2014 Jul 1;20(13):3623-4. doi: 10.1158/1078-0432.CCR-13-3256. Epub 2014 May 6. No abstract available.

PMID:
24803580
[PubMed - in process]
4.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
[PubMed - in process]
5.

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.

Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16.

PMID:
23860535
[PubMed - indexed for MEDLINE]
6.

"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma.

Giovannetti E, Peters GJ, Zucali PA.

J Thorac Oncol. 2013 Aug;8(8):e79-80. doi: 10.1097/JTO.0b013e318293e45b. No abstract available.

PMID:
23857408
[PubMed - indexed for MEDLINE]
7.

Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.

Petrini I, Wang Y, Zucali PA, Lee HS, Pham T, Voeller D, Meltzer PS, Giaccone G.

Clin Cancer Res. 2013 Apr 15;19(8):1960-71. doi: 10.1158/1078-0432.CCR-12-3260. Epub 2013 Feb 26.

PMID:
23444221
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.

Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J.

Br J Cancer. 2013 Jan 15;108(1):21-4. doi: 10.1038/bjc.2012.556. Epub 2013 Jan 3.

PMID:
23287988
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Reproducibility of the WHO classification of thymomas: practical implications.

Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G.

Lung Cancer. 2013 Mar;79(3):236-41. doi: 10.1016/j.lungcan.2012.11.015. Epub 2012 Dec 29.

PMID:
23279873
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours.

Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A.

Br J Cancer. 2013 Jan 15;108(1):58-63. doi: 10.1038/bjc.2012.506. Epub 2012 Nov 20.

PMID:
23169299
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

Simonelli M, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A.

Eur J Cancer. 2013 Mar;49(5):989-98. doi: 10.1016/j.ejca.2012.10.016. Epub 2012 Nov 9.

PMID:
23146956
[PubMed - indexed for MEDLINE]
12.

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, Roncalli M, Steinberg SM, Wang Y, Giaccone G.

Cell Death Dis. 2012 Jul 19;3:e351. doi: 10.1038/cddis.2012.92.

PMID:
22825469
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Anti-angiogenic therapies for malignant pleural mesothelioma.

Ceresoli GL, Zucali PA.

Expert Opin Investig Drugs. 2012 Jun;21(6):833-44. doi: 10.1517/13543784.2012.681641. Epub 2012 Apr 23. Review.

PMID:
22519641
[PubMed - indexed for MEDLINE]
14.

NUT rearrangement is uncommon in human thymic epithelial tumors.

Petrini P, French CA, Rajan A, Cameron MJ, Jaffe ES, Zucali PA, Xie J, Wang Y, Giaccone G.

J Thorac Oncol. 2012 Apr;7(4):744-50. doi: 10.1097/JTO.0b013e3182460f8f.

PMID:
22425924
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ.

Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4.

PMID:
21970874
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
[PubMed - indexed for MEDLINE]
17.

Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.

De Vincenzo F, Zucali PA, Ceresoli GL, Colombo P, Simonelli M, Lorenzi E, Perrino M, Gianoncelli L, De Sanctis R, Graziotti P, Santoro A.

J Clin Oncol. 2011 Jun 20;29(18):e529-31. doi: 10.1200/JCO.2011.34.8284. Epub 2011 Apr 11. No abstract available.

PMID:
21483010
[PubMed - indexed for MEDLINE]
18.

Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.

León LG, Giovannetti E, Alecci C, Giancola F, Funel N, Zucali P, Peters GJ, Padrón JM.

In Vivo. 2011 Mar-Apr;25(2):203-7.

PMID:
21471536
[PubMed - indexed for MEDLINE]
19.

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.

Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M.

Ann Oncol. 2012 Jan;23(1):59-64. doi: 10.1093/annonc/mdr052. Epub 2011 Apr 2.

PMID:
21460378
[PubMed - indexed for MEDLINE]
Free Article
20.

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ.

Pharmacogenomics. 2011 Feb;12(2):159-70. doi: 10.2217/pgs.10.172.

PMID:
21332310
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk